Congress caps epinephrine costs at $60 for insured patients

What it does

This bill requires health insurance plans to cover epinephrine delivery systems (EpiPens, nasal sprays, and similar devices) with no deductible and a maximum out-of-pocket cost of $60 per package of two devices. The requirement applies to group health plans, employer-sponsored insurance, and individual insurance policies. Plans may still charge higher costs for out-of-network providers.

Why we flagged it

The bill's operative mechanism is a price cap and deductible waiver for a specific essential medication class, designed to reduce out-of-pocket costs for patients with severe allergies. This is straightforward consumer protection legislation, not a hidden subsidy or regulatory carve-out.

What the text implies

• The $60 cap may incentivize insurers to negotiate lower wholesale prices with manufacturers, potentially reducing prices across the market beyond just the insured population.
• Out-of-network carve-out allows plans to charge higher costs for out-of-network epinephrine, which may disadvantage patients in rural areas or those without in-network access to these devices.
• The bill does not address the underlying manufacturer pricing or patent protections that have historically driven epinephrine costs upward, leaving structural price drivers untouched.
• Plans may respond by narrowing their formularies or restricting which epinephrine delivery systems are covered in-network, shifting patient choice toward specific products.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Ordinary people with severe allergies gain guaranteed affordable access to life-saving medication without deductible barriers, reducing financial obstacles to emergency treatment. The $60 cap is substantially lower than current market prices for epinephrine auto-injectors (typically $300–$600 per pair), making the medication accessible to more people who need it.

Who stands to gain

• patients with severe allergies (primary beneficiary)
• employers offering health plans (reduced employee out-of-pocket costs may improve retention and prod

Named in the bill

FDA, Johnson & Johnson (Mylan subsidiary, EpiPen manufacturer), Kaleo (Auvi-Q manufacturer), Adamis Pharmaceuticals (Symjepi manufacturer), group health plans, health insurance issuers, employers

Where it stands

1 cosponsor: 1 Democrats.

• Sep 4, 2025 — Introduced · Congress.gov: “Introduced in House”
• Sep 4, 2025 — Referred to House Committee on Ways and Means and House Committee on Education and Workforce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committees on Education and…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.